Acadia snags Amgen, Horizon vet to direct R&D; Samantha Truex steps down as Upstream Bio CEO
→ Just a few weeks after Amgen touted its efforts in rare disease, EVP of R&D in that therapeutic area is departing to lead R&D at Acadia Pharmaceuticals. Elizabeth Thompson will steer research and development at the neuroscience drugmaker after serving in key roles on the pre- and post-marketing work of Horizon’s medicines. She contributed to Tepezza, Krystexxa and Uplizna, among other drugs, during her time at the Chicago and Ireland biopharma, which Amgen bought last year for nearly $28 billion. She joins Acadia about 13 months after it secured its second FDA approval. Her career includes a prior 10-year tenure at Amgen and roles at InterMune, Raptor and AbbVie.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
